世界の乾癬治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV04406)
◆英語タイトル:Global Psoriasis Therapeutics Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV04406
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:93
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは乾癬治療薬の世界市場について調査・分析した資料です。種類別(TNF阻害剤、PDE4阻害剤、インターロイキン遮断薬、その他)の市場規模、用途別(経口、非経口、局所)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別乾癬治療薬の競争状況、市場シェア
・世界の乾癬治療薬市場:種類別市場規模 2015年-2020年(TNF阻害剤、PDE4阻害剤、インターロイキン遮断薬、その他)
・世界の乾癬治療薬市場:種類別市場規模予測 2021年-2026年(TNF阻害剤、PDE4阻害剤、インターロイキン遮断薬、その他)
・世界の乾癬治療薬市場:用途別市場規模 2015年-2020年(経口、非経口、局所)
・世界の乾癬治療薬市場:用途別市場規模予測 2021年-2026年(経口、非経口、局所)
・北米の乾癬治療薬市場分析:米国、カナダ
・ヨーロッパの乾癬治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの乾癬治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の乾癬治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの乾癬治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Astellas Pharma Inc.、AstraZeneca plc、Boehringer Ingelheim GmbH、F. Hofffmann-La Roche、GlaxoSmithKline plc、Merck & Co., Inc.、Valeant Pharmaceuticals International, Inc.、Biocon Limited、Eli Lilly and Company、G & W Laboratories Inc.
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Psoriasis is considered to be a persistent skin disorder that is characterized mainly by skin irritation and scaly rashes where the skin cells multiply up to 10 times faster than normal. Psoriasis majorly affects the knees, elbows, and scalp. The major objective of the therapy for this disease is to stop the skin cells from growing so quickly. The therapeutic approach for psoriasis depends upon the severity and amount of skin affected by the same.

Market Analysis and Insights: Global Psoriasis Therapeutics Market
The global Psoriasis Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Psoriasis Therapeutics Scope and Market Size
Psoriasis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Psoriasis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Astellas Pharma Inc.
AstraZeneca plc
Boehringer Ingelheim GmbH
F. Hofffmann-La Roche
GlaxoSmithKline plc
Merck & Co., Inc.
Valeant Pharmaceuticals International, Inc.
Biocon Limited
Eli Lilly and Company
G & W Laboratories Inc.

Market segment by Type, the product can be split into
TNF Inhibitors
PDE4 Inhibitors
Interleukin Blockers
Others
Market segment by Application, split into
Oral
Parenteral
Topical

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Psoriasis Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Psoriasis Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 TNF Inhibitors
1.4.3 PDE4 Inhibitors
1.4.4 Interleukin Blockers
1.4.5 Others
1.5 Market by Application
1.5.1 Global Psoriasis Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Oral
1.5.3 Parenteral
1.5.4 Topical
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Psoriasis Therapeutics Market Perspective (2015-2026)
2.2 Global Psoriasis Therapeutics Growth Trends by Regions
2.2.1 Psoriasis Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Psoriasis Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Psoriasis Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Psoriasis Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Psoriasis Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Psoriasis Therapeutics Players by Market Size
3.1.1 Global Top Psoriasis Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Psoriasis Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Psoriasis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Psoriasis Therapeutics Market Concentration Ratio
3.2.1 Global Psoriasis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Psoriasis Therapeutics Revenue in 2019
3.3 Psoriasis Therapeutics Key Players Head office and Area Served
3.4 Key Players Psoriasis Therapeutics Product Solution and Service
3.5 Date of Enter into Psoriasis Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Psoriasis Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Psoriasis Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Psoriasis Therapeutics Market Size by Application (2015-2020)
5.2 Global Psoriasis Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Psoriasis Therapeutics Market Size (2015-2020)
6.2 Psoriasis Therapeutics Key Players in North America (2019-2020)
6.3 North America Psoriasis Therapeutics Market Size by Type (2015-2020)
6.4 North America Psoriasis Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Psoriasis Therapeutics Market Size (2015-2020)
7.2 Psoriasis Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Psoriasis Therapeutics Market Size by Type (2015-2020)
7.4 Europe Psoriasis Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Psoriasis Therapeutics Market Size (2015-2020)
8.2 Psoriasis Therapeutics Key Players in China (2019-2020)
8.3 China Psoriasis Therapeutics Market Size by Type (2015-2020)
8.4 China Psoriasis Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Psoriasis Therapeutics Market Size (2015-2020)
9.2 Psoriasis Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Psoriasis Therapeutics Market Size by Type (2015-2020)
9.4 Japan Psoriasis Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Psoriasis Therapeutics Market Size (2015-2020)
10.2 Psoriasis Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Psoriasis Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Psoriasis Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Psoriasis Therapeutics Market Size (2015-2020)
11.2 Psoriasis Therapeutics Key Players in India (2019-2020)
11.3 India Psoriasis Therapeutics Market Size by Type (2015-2020)
11.4 India Psoriasis Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Psoriasis Therapeutics Market Size (2015-2020)
12.2 Psoriasis Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Psoriasis Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Psoriasis Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Astellas Pharma Inc.
13.1.1 Astellas Pharma Inc. Company Details
13.1.2 Astellas Pharma Inc. Business Overview
13.1.3 Astellas Pharma Inc. Psoriasis Therapeutics Introduction
13.1.4 Astellas Pharma Inc. Revenue in Psoriasis Therapeutics Business (2015-2020))
13.1.5 Astellas Pharma Inc. Recent Development
13.2 AstraZeneca plc
13.2.1 AstraZeneca plc Company Details
13.2.2 AstraZeneca plc Business Overview
13.2.3 AstraZeneca plc Psoriasis Therapeutics Introduction
13.2.4 AstraZeneca plc Revenue in Psoriasis Therapeutics Business (2015-2020)
13.2.5 AstraZeneca plc Recent Development
13.3 Boehringer Ingelheim GmbH
13.3.1 Boehringer Ingelheim GmbH Company Details
13.3.2 Boehringer Ingelheim GmbH Business Overview
13.3.3 Boehringer Ingelheim GmbH Psoriasis Therapeutics Introduction
13.3.4 Boehringer Ingelheim GmbH Revenue in Psoriasis Therapeutics Business (2015-2020)
13.3.5 Boehringer Ingelheim GmbH Recent Development
13.4 F. Hofffmann-La Roche
13.4.1 F. Hofffmann-La Roche Company Details
13.4.2 F. Hofffmann-La Roche Business Overview
13.4.3 F. Hofffmann-La Roche Psoriasis Therapeutics Introduction
13.4.4 F. Hofffmann-La Roche Revenue in Psoriasis Therapeutics Business (2015-2020)
13.4.5 F. Hofffmann-La Roche Recent Development
13.5 GlaxoSmithKline plc
13.5.1 GlaxoSmithKline plc Company Details
13.5.2 GlaxoSmithKline plc Business Overview
13.5.3 GlaxoSmithKline plc Psoriasis Therapeutics Introduction
13.5.4 GlaxoSmithKline plc Revenue in Psoriasis Therapeutics Business (2015-2020)
13.5.5 GlaxoSmithKline plc Recent Development
13.6 Merck & Co., Inc.
13.6.1 Merck & Co., Inc. Company Details
13.6.2 Merck & Co., Inc. Business Overview
13.6.3 Merck & Co., Inc. Psoriasis Therapeutics Introduction
13.6.4 Merck & Co., Inc. Revenue in Psoriasis Therapeutics Business (2015-2020)
13.6.5 Merck & Co., Inc. Recent Development
13.7 Valeant Pharmaceuticals International, Inc.
13.7.1 Valeant Pharmaceuticals International, Inc. Company Details
13.7.2 Valeant Pharmaceuticals International, Inc. Business Overview
13.7.3 Valeant Pharmaceuticals International, Inc. Psoriasis Therapeutics Introduction
13.7.4 Valeant Pharmaceuticals International, Inc. Revenue in Psoriasis Therapeutics Business (2015-2020)
13.7.5 Valeant Pharmaceuticals International, Inc. Recent Development
13.8 Biocon Limited
13.8.1 Biocon Limited Company Details
13.8.2 Biocon Limited Business Overview
13.8.3 Biocon Limited Psoriasis Therapeutics Introduction
13.8.4 Biocon Limited Revenue in Psoriasis Therapeutics Business (2015-2020)
13.8.5 Biocon Limited Recent Development
13.9 Eli Lilly and Company
13.9.1 Eli Lilly and Company Company Details
13.9.2 Eli Lilly and Company Business Overview
13.9.3 Eli Lilly and Company Psoriasis Therapeutics Introduction
13.9.4 Eli Lilly and Company Revenue in Psoriasis Therapeutics Business (2015-2020)
13.9.5 Eli Lilly and Company Recent Development
13.10 G & W Laboratories Inc.
13.10.1 G & W Laboratories Inc. Company Details
13.10.2 G & W Laboratories Inc. Business Overview
13.10.3 G & W Laboratories Inc. Psoriasis Therapeutics Introduction
13.10.4 G & W Laboratories Inc. Revenue in Psoriasis Therapeutics Business (2015-2020)
13.10.5 G & W Laboratories Inc. Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Astellas Pharma Inc.、AstraZeneca plc、Boehringer Ingelheim GmbH、F. Hofffmann-La Roche、GlaxoSmithKline plc、Merck & Co., Inc.、Valeant Pharmaceuticals International, Inc.、Biocon Limited、Eli Lilly and Company、G & W Laboratories Inc.

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の乾癬治療薬市場2026:インサイト・予測(Global Psoriasis Therapeutics Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。